Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Future directions for unsealed source radionuclide therapy for bone metastases.

× No keyword cloud information.

26 in total

1. A direct measurement of strontium-89 activity in bone metastases.

Authors: E Ben-Josef; R L Maughan; S Vasan; A T Porter
Journal: Nucl Med Commun Date: 1995-06 Impact factor: 1.690

Review 2. Targeted radionuclide therapy for bone metastases.

Authors: V J Lewington
Journal: Eur J Nucl Med Date: 1993-01

3. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.

Authors: J H Turner; P G Claringbold
Journal: Eur J Cancer Date: 1991 Impact factor: 9.162

4. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).

Authors: A Berruti; S Cerutti; G Fasolis; P Sperone; R Tarabuzzi; O Bertetto; G Pagani; R Zolfanelli; S Pallotti; C Bumma; D Fontana; S R Rosseti; L Dogliotti; A Angeli
Journal: Anticancer Res Date: 1997 Nov-Dec Impact factor: 2.480

5. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases.

Authors: H Palmedo; S Guhlke; H Bender; J Sartor; G Schoeneich; J Risse; F Grünwald; F F Knapp; H J Biersack
Journal: Eur J Nucl Med Date: 2000-02

6. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.

Authors: Peter M Anderson; Gregory A Wiseman; Angela Dispenzieri; Carola A S Arndt; Lynn C Hartmann; William A Smithson; Brian P Mullan; Oyvind S Bruland
Journal: J Clin Oncol Date: 2002-01-01 Impact factor: 44.544

7. Phosphorus-32 for intractable bony pain from carcinoma of the prostate.

Authors: N G Burnet; G Williams; N Howard
Journal: Clin Oncol (R Coll Radiol) Date: 1990-07 Impact factor: 4.126

8. Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation.

Authors: E Ben-Josef; D R Lucas; S Vasan; A T Porter
Journal: Nucl Med Commun Date: 1995-06 Impact factor: 1.690

9. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.

Authors: J J Pollen; K F Witztum; W L Ashburn
Journal: AJR Am J Roentgenol Date: 1984-04 Impact factor: 3.959

10. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group.

Authors:
Journal: Lancet Date: 1995-07-29 Impact factor: 79.321

5 in total

Future directions for unsealed source radionuclide therapy for bone metastases.

1. A direct measurement of strontium-89 activity in bone metastases.

Review 2. Targeted radionuclide therapy for bone metastases.

3. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.

4. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).

5. Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases.

6. High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.

7. Phosphorus-32 for intractable bony pain from carcinoma of the prostate.

8. Selective accumulation of strontium-89 in metastatic deposits in bone: radio-histological correlation.

9. The flare phenomenon on radionuclide bone scan in metastatic prostate cancer.

10. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group.

1. Enhancement of uptake of therapeutic radiopharmaceuticals in bone lesions.

2. Radionuclide therapy in oncology: repeated administrations of high dose rate radiopharmaceuticals.

Review 3. Radiation-induced bystander signalling in cancer therapy.

Review 4. 186Re-HEDP for metastatic bone pain in breast cancer patients.

Review 5. 153Sm-EDTMP for bone pain palliation in skeletal metastases.